Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review

Onco Targets Ther. 2014 Jul 31:7:1361-6. doi: 10.2147/OTT.S65774. eCollection 2014.

Abstract

Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports. Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy.

Keywords: CDDP; PTX; chemotherapy; cytotoxic drugs; oncology.

Publication types

  • Case Reports